anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A composition for enhancing percutaneous absorption of a pharmaceutical substance contains a proline ester (I) or prolinol ester (II) <CHEM> wherein R1 and R3 are hydrogen or aliphatic hydrocarbon residue, R2 and R4 are aliphatic hydrocarbon residues, the carbon atoms not exceeding 20 in R1 and R2 and 18 in R3 and R4, and the ring N-atom can be quaternised to form a salt with an acid; synthesis of these compounds is described. Usually a polar liquid is included e.g. an alcohol, glycerin or an ester thereof, a thioglycerol, lactic ester, ethyleneurea amide, glycol, lactone, pyrrolidone or lactam compound, in amount of 30-99.5 wt% of the ester and polar compound. The active ingredient can be applied separately to the skin or preferably incorporated in the composition, to provide topical or systemic effects. Numerous types of ingredients can be used. The composition can be incorporated in an ointment, lotion, gel, plaster or tape.
Adesh is a synthetic peptide consisting of at least the first four amino acids from the N-terminal of the sequence N L G E H P V C D S T D T W V (SEQ. ID. NO.: 1) and no more than 25 amino acids total. The synthetic peptide mimics the biological properties of nerve growth factor (NGF) consisting of 116 amino acids and is advocated to treat Down Syndrome (DS) and schizophrenia. It is believed that these neuro-degenerative diseases are linked with inadequate neurotrophic factors.
Aspirin 150mg once daily and Losartan 100mg once daily. Losartan dose may be stopped or reduced if patient is hypotensive and can be restarted anytime during the treatment period.
The present invention provides an external skin application composition for ameliorating atopic dermatitis, comprising, as an active ingredient, fermented soybeans and at least one of fermented tomatoes or fermented mulberries. According to the present invention, the external skin application composition includes both a cosmetic composition and a pharmaceutical composition. In addition, economical and eco-friendly ingredients are used in the composition. Thus, the composition is gentle on skin and effective in relieving contact dermatitis, inflammation, and itchy skin. Particularly, the composition has excellent efficacy on atopic dermatitis and is mild on skin while retaining the efficacy thereof. Furthermore, the composition is suitable to produce various types of cosmetics and medical substances owing to excellent stability of a formulation, thereby contributing to the production of a product suitable to convenience of a user.
Dietary micronutrients are integral to the development and progression of constipation; however, the specific relationship between dietary copper intake and constipation has not been thoroughly investigated. This study aims to examine the correlation between dietary copper intake and constipation among U.S. adults, thereby offering novel insights and recommendations for the clinical management and prevention of constipation. Bowel health data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2005 and 2010 were analyzed. Subjects' dietary information was collected through questionnaire records. Multivariate logistic regression analysis, subgroup analysis, and curve fitting analysis were used to assess the correlation between dietary copper intake and chronic constipation. After adjusting for all possible confounders, each unit increase in dietary copper intake (converted to natural logarithms) was associated with a 20% reduction in the prevalence of constipation (OR = 0.80; 95% CI 0.65-0.98; P = 0.037). The interaction P-values for all subgroups were greater than 0.05, indicating that the findings were stable and consistent across subgroups. The present study showed a significant negative association between dietary copper intake and chronic constipation in adults. This finding raises clinical and healthcare professionals' awareness of the impact of dietary trace elements on intestinal health and has important implications for the development of personalized meal plans and rational supplementation of trace copper in patients with constipation.
The antihypertensive efficacy of SULAR was studied in 5 double-blind, placebo-controlled, randomized studies, in which over 600 patients were treated with SULAR as monotherapy and about 300 with placebo; 4 of the five studies compared 2 or 3 fixed doses while the fifth allowed titration from doses bioequivalent to 8.5 - 34 mg. Once daily administration of SULAR produced sustained reductions in systolic and diastolic blood pressures over the 24 hour dosing interval in both supine and standing positions. The mean placebo-subtracted reductions in supine systolic and diastolic blood pressure at trough, 24 hours post-dose, in these studies, are shown below. Changes in standing blood pressure were similar:

In patients receiving atenolol, supine blood pressure reductions with SULAR doses bioequivalent to 17 and 34 mg once daily were 12/6 and 19/8 mm Hg, respectively. The sustained antihypertensive effect of SULAR was demonstrated by 24 hour blood pressure monitoring and examination of peak and trough effects. The trough/peak ratios ranged from 70 to 100% for diastolic and systolic blood pressure. The mean change in heart rate in these studies was less than one beat per minute. In 4 of the 5 studies, patients received intial doses bioequivalent to 17-25.5 mg SULAR without incident (excessive effects on blood pressure or heart rate). The fifth study started patients on lower doses of SULAR.

Patient race and gender did not influence the blood pressure lowering effect of SULAR. Despite the higher plasma concentration of nisoldipine in the elderly, there was no consistent difference in their blood pressure response except that the lowest clinical dose was somewhat more effective than in non-elderly patients. No postural effect on blood pressure was apparent and there was no evidence of tolerance to the antihypertensive effect of SULAR in patients treated for up to one year.
The present invention relates to a nursing support system for patient safety which protects patients from an accident and can immediately respond to the requests of patients for nursing through monitoring thereof. The nursing support system for patient safety includes a server, a monitoring unit, a display unit, a fall prevention unit, and a nurse center. The server stores the database about the medical information of the patient to which a unique ID is assigned. The monitoring unit is linked with the server to check the medical information of the patient and enables input of additional medical information. The display unit outputs screen information transmitted from the monitoring unit and transmits a nurse call signal to the outside according to a command inputted from the patient. The fall prevention unit receives load data outputted from a plurality of pressure sensors provided on the bed of the patient, analyzes the load data, and transmits a danger signal to the outside when the load data is abnormal. The nurse center receives the nurse call signal and the danger signal and outputs a warning signal to a nurse.
BACKGROUND: Alzheimer's disease (AD) heritability is estimated to be around 70-80%. Yet, much of it remains to be explained. Studying transmission patterns may help in understanding other factors contributing to the development of AD.
OBJECTIVE: In this study, we aimed to search for evidence of autosomal recessive or X- and Y-linked inheritance of risk factors in a large cohort of Portuguese AD patients.
METHODS: We collected family history from patients with AD and cognitively healthy controls over 75 years of age. We compared the proportions of maternal and paternal history in male and female patients and controls (to search for evidence of X-linked and Y-linked inherited risk factors). We compared the risk of developing AD depending on parents' birthplace (same vs. different), as a proxy of remote consanguinity. We performed linear regressions to study the association of these variables with different endophenotypes.
RESULTS: We included 3090 participants, 2183 cognitively healthy controls and 907 patients with AD. Men whose mother had dementia have increased odds of developing AD comparing to women whose mother had dementia. In female patients with a CSF biomarker-supported diagnosis of AD, paternal history of dementia is associated with increased CSF phosphorylated Tau levels. People whose parents are from the same town have higher risk of dementia. In multivariate analysis, this proxy is associated with a lower age of onset and higher CSF phosphorylated tau.
CONCLUSIONS: Our study gives evidence supporting an increased risk of developing AD associated with an X-linked inheritance pattern and remote consanguinity.
The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
The invention relates to a process for preparing an avian influenza inactivated vaccine by full suspended culture cells and a product. The avian influenza inactivated vaccine product is prepared by the following steps: inoculating an avian influenza virus by the full suspended culture MDCK cells; clarifying, inactivating, degerming, concentrating and purifying and emulsifying the obtained avian influenza virus liquid. Compared with the prior art, the process provided by the invention is optimal and low in cost. Under the condition of guaranteeing the virus titer, the MDCK cell culture density can be greatly improved by the process provided by the invention, so that amplification on a large scale is easy to realize, and the avian influenza virus is proliferated in a great quantity. Compared with existing carrier suspended culture, the process provided by the invention is free from carrier intervention, so that the risk on pollution is greatly reduced. The process provided by the invention efficiently solves the problems of high pollution rate, low antigen output, long production period, insufficient SPF chicken embryo supply and the like of a chicken embryo method and is suitable for popularization and application of the reactor cell suspension culture technology in the avian influenza industry.
Viscosupplementation by intra-articular injection of hyaluronate products has recently gained popularity as a treatment modality of gonarthritis. Hyaluronic Acid is responsible for the elasticity and viscosity of the synovial fluid, protecting the joint. Biopsy studies show that besides the gain in pain and function, viscosupplementation may lead to structural changes of the cartilage. Currently there are several studies on the effect of intra-articular injection of hyaluronic acid in gonarthritis. There is not, however, a consensus on the best method. Regarding the substance to be injected, corticosteroids alone exhibit rapid results, but poor durability. Viscosupplementation shows more consistent results. However, especially when using derivatives with higher molecular weight hyaluronan, there is a significant number of patients that present an acute synovial reaction to viscosupplementation specially in the first cycle of three injections. The association triamcinolone injection with hyaluronic acid decreases the complaints in the first month of treatment. Our objective is to evaluate what is the best dosage of viscosupplementation with hyaluronic acid (OSTEONIL®) associated with 1 ml (20 mg) of triamcinolone hexacetonide by comparing two groups of patients with knee OA, the first with a single application of 3 ampoules and second with three applications, one per week for three weeks. One hundred and four knee osteoarthritis (KOA) patients, which are currently in usual care for KOA at the Osteometabolic Group - Department of Orthopedics and Traumatology - University of São Paulo General Hospital - will be assessed. After signing the informed consent, participants will respond WOMAC™, Lequesne™, VAS, SF-36 (quality of life) and subjective IKDC (International Knee Documentation Committee). The questionnaires and functional assessment will be performed before the procedure infiltration with 1month, 3 months, 6 months and 1 year of intervention.Twenty Patients will be submitted to evaluation using force platform and balance NeuroCom ®, with the following tests: weight support during the squat (weight bearing squat (WBS), one-leg support (unilateral stance (U.S.), from sitting to foot (sit to stand - STS). Previously, at 1 month, 3 month, 6 month and 12 months after the intervention.

Frontal weight-bearing, profile and axial radiographs will be performed to radiologically assess participants' knees.Patients will be randomly divided into two groups of 54 patients, (groups 1 and 2). Patients in group 1 (G1) will be submitted to viscosupplementation with 1 application of 3 vials of hyaluronic acid 20mg/2ml (OSTEONIL®) and 1 ml (20 mg) triamcinolone, whereas group 2 patients will be submitted to viscosupplementation with three applications of one ampoule of hyaluronic acid 20 mg/2ml (one per week for three weeks), with the first application of OSTEONIL® with 1 ml (20 mg) triamcinolone.
A transposable element is provided that as a 3' and a 5' end. The transposable element includes a 5' recombining site 5' of a nucleic acid sequence encoding a selectable marker, a 3' recombining site 3' of the nucleic acid sequence encoding a selectable marker, a nucleic acid sequence encoding and MHC epitope 5' to the 5' recombining site or 3' to the 3' recombining site, and an insertion end comprising an inverted repeat sequence sufficient for integration of the transposable element at the 5' and the 3' end of the transposable element. In one embodiment, a transposable element is provided that has a 5' and a 3' end. The transposable element includes a 5' loxP  sequence 5' of a nucleic acid encoding a selectable marker, a 3' loxP  sequences 3' of a nucleic acid encoding the selectable marker, an MHC epitope 5' to the 5' loxP sequences or 3' of the 3' loxP sequence, an insertion end at the 5' end of the transposable element, and an insertion end at the 3' of the transposable element. A method is provided for detecting an antigenic epitope of a pathogen by infecting a pathogenic cell with a transposable element of the invention, wherein the infection results in the integration of the transposable element in a nucleic acid sequence of the bacterial cell;  transforming the pathogenic cell with a vector comprising a transposase;  contacting a eukaryotic cell that can internalize the pathogenic cell with the pathogenic cell infected with the transposable element; contacting the eukaryotic cell with a specific binding partner that recognizes the MHC  epitope; identifying the labeled eukaryotic cells and externalizing the bacteria cell. The externalized bacterial cell may be grown to produce a population of bacterial cells, and the nucleic acid sequence of the bacterial cell that has the integrated transposable element is identified. This nucleic acid sequence encodes the antigenic element of the panthogen. A method is also provided for generating a carrier vaccine by infecting a bacterial cell with the transposable element of the invention, wherein the transposable further comprises an antigen associated with a disease operably linked to the MHC  epitope of the transposable element. The infection of the bacteria results in the integration of the transposable element in a nucleic acid sequence of the bacterial cell. The pathogenic cell is then internalized into a eukaryotic cell and the eukaryotic cell is exposed to a specific bindind agent that recognizes the MHC epitope, identifying labeled eukaryotic cells are identified and lysed to externalize the bacteria cell, which is cultured to produce a population of bacterial cells. The nucleic acid sequence of the bacterial cell that has the integrated transposable element is identified, wherein the nucleic acid sequence encodes the antigenic element of the pathogen. The graving bacterial cell identified, and may be used as the carrier vaccine.
The approval of pharmaceuticals in response to the COVID-19 pandemic is a global concern, and during emergencies, emergency approval or authorization systems that enable the rapid use of unapproved drugs to maintain national health are essential. However, there is limited research comparing these systems across countries and their effects. This cross-sectional study examined such systems in Japan (JP), Europe (EU), the United Kingdom (UK), and China (CN) for pharmaceuticals (n = 23) authorized under Emergency Use Authorization (EUA) in the United States (US) between December 2019 to July 2023. As of the end of July 2023, JP had granted approval or permission for 14 drugs (60.9%), EU for 14 (60.9%), UK for 12 (52.2%), and CN for three (13.0%). An examination of the developmental status of the 23 drugs revealed that JP had 6 drugs (26.1%), the EU had 3 drugs (8.7%), the UK had 5 drugs (21.7%), and CN had 16 drugs (69.6%) yet to be developed. The US had significantly more granted permissions and developed drugs, while CN the least. The UK had a significantly shorter period for approval than the US and the shortest overall. The EU had the shortest period from the issuance of EUA to approval dates. Although not statistically significant, JP had the longest duration until unapproved drugs could be used. Pharmaceuticals granted usage permission under the EUA in JP, the EU, and the UK were developed or on the market in over 70% of cases, whereas in CN, more than two-thirds were yet to be developed. This suggests that CN may not actively utilize pharmaceuticals from other countries for COVID-19 treatment and may rely on its own. When comparing the emergency approval and permission systems of each country, the most significant difference was in the type of system granting approval.
PURPOSE:To profitably obtain the subject compound useful as a carcinostatic agent, etc., by determining the whole amino acid sequence of the phenomycin, preparing an expression vector containing its DNA fragment on the basis of the determination result, transforming Escherichia coli with the prepared expression vector and subsequently culturing the transformant. CONSTITUTION:An Actinomyces, Streptomyces fervens var, phenomyceticus is rotation-cultured in a medium at 27 deg.C for 72hr, and the culture solution is filtered. The filtrate is applied to a cation exchange column, and the adsorbed substance is eluted and purified by a high performance liquid chromatography. The amino acid sequence of the collected phenomycin is determined, and on the determined amino acid sequence, a gene coding the phenomycin having the amino acid sequence of the formula is synthesized with a DNA synthesizing machine. The synthesized gene is multiplied by a PCR method, combined with a vector and subsequently introduced into Escherichia coli. The produced transformant is cultured to massively and profitably produce the objective phenomycin of the formula.
Systemic concentrations of Te, E2, GH, Insulin-like Growth Factor-I and IGFBP-3 decline in healthy aging men. Relative sex-steroid deprivation accentuates GH and IGF-I depletion, since Te stimulates GH and IGF-I production in older men, hypogonadal males of all ages, and patients undergoing (genotypic female-to-male) gender reassignment. Tamoxifen blocks this effect of Te, suggesting involvement of E2 in GH's stimulation in men. E2 per se stimulates GH secretion in women. Because Te is converted to E2 by aromatization in the body, we postulate that E2 is the active moiety in men also. Moreover, we hypothesize that the decline of E2 in older men contributes to the fall in GH output. This has never been tested. From a clinical vantage, understanding the mechanistic basis of Te's drive of the somatotropic axis is especially relevant in boys with pubertal failure, adults with primary hypogonadism and men with aging-related hypoandrogenemia. In relation to aging in the male, testosterone and E2 bioavailabilities fall by 35-50% in the eighth compared with third decade of life. From a medical perspective, aging is accompanied by progressive osteopenia, sarcopenia and intra-abdominal obesity. These adverse outcomes are remediable by short-term replacement with Te and/or recombinant GH, thus linking GH/Te/E2 availability with key body-compositional features.
In this study, the purpose of the study was explained to the women from intervention group and their partners by visiting them in their home. Personal Information Form (PIF), Pittsburgh Sleep Quality Index (PSQI), Menopause Symptoms Rating Scale (MSRS) and Marital Adjustment Scale (MAS) were filled by the women and MAS was filled by their partners. Firstly, back massage was taught to the partners of women in the intervention group. The massage was made half an hour before the women's sleep time for a total of 15 minutes. Partners were ensured to apply this massage twice a week for four weeks. The intervention group was called by telephone every week to ensure continuity of the study. By visiting those at their homes again at the end of the fourth week, PSQI, MSRS, and MAS were filled by the women and MAS was filled by their husbands for the last time.
In the experimental group, twice a day, in the morning and evening, and 30 minutes after the meal, for 15 minutes. Effusion, petrissage and vibration massage movements will be applied by the researcher for a certain period of time in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.
OBJECTIVE: High-grade aneuploidies of X and Y sex chromosomes (HGAs) are exceedingly rare and complex conditions. We aimed to investigate the effect of supernumerary X chromosomes (extra-Xs) on the clinical, hormonal, metabolic, and echocardiographic features of patients with HGAs.
DESIGN AND METHODS: In a cross-sectional study, we compared 23 subjects with HGAs and 46 age-matched subjects with 47,XXY Klinefelter syndrome (KS), according to the number of extra-Xs: two (47,XXY and 48,XXYY), three (48,XXXY and 49,XXXYY), or four supernumerary Xs (49,XXXXY). A second cohort consisting of 46 pubertal stage-matched KS subjects was employed for validation. Clinical, hormonal, metabolic and ultrasonographic parameters were collected and analyzed.
RESULTS: The increase in the number of extra-Xs was associated with a progressive adverse effect on height, pubertal development, testicular volume and function, adrenal steroidogenesis, and thyroid function. A progressive linear increase in ACTH and a decrease in cortisol/ACTH ratios were found. Weight and body mass index, Sertoli cell function, lipid profile, and glucose tolerance post-oral glucose tolerance test were all worse in the HGA cohort compared to KS. Cardiac evaluation revealed a linear association with reduced left and right end-diastolic diameters and reduced ejection fraction.
CONCLUSION: The increase in the number of extra-Xs is associated with a "dose-dependent" progressive impairment in steroid producing glands, thyroid function, cardiac structure, and performance.